FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955288519> ?p ?o ?g. }

• W2955288519 endingPage "5134" @default.
• W2955288519 startingPage "5134" @default.
• W2955288519 abstract "Abstract Background: Precision oncology highlights the individualization of diagnosis, prognosis and treatment based on molecular stratification of cancer patients (pts). Genetic patterns in many types of cancer vary among geographical regions, leading to variation in evidence-based recommendations for clinical management of pts. Genomic alterations (GAs) of solid tumors from Chinese pts have not been fully studied across all cancer types. Methods: Tumor tissues and matched blood from 5355 Chinese pts were collected and sequenced by a next generation sequencing based 450-gene panel assay. About 60% of the samples were FFPE tissues. In our study, 59% were males and 41% were females with a median age of 58 years old (range 1-92). The major cancer types were NSCLC (36%), CRC (8%), HCC (7%), gastric cancer (5%), pancreatic cancer (5%), and also cholangiocarcinoma, esophageal carcinoma, SCLC, gallbladder carcinoma, ovarian cancer, breast cancer, head and neck cancer, sarcoma, renal carcinoma, uterine neoplasms and others. 1% were pediatric patients . Single base substitutions, short and long insertions/deletions (indels), copy number alterations (CNA), fusions/rearrangements, TMB and MSI status were assessed by NGS. Results: On average, our study identified 7 mutations per patient. Gene rearrangements and long indels (50bp - 2k) were detected in 15% and 5% of the cancers. In total, 58% of pts harbored GAs in druggable genes defined as targets of FDA approved drugs. Highest mutation frequencies were found in TP53 (60%), EGFR (23%), KRAS (18%), CDKN2A (13%), TERT (12%), PIK3CA (11%), APC (11%), LRP1B (10%), ARID1A (9%), and RB1 (8%) across all tumor types. The frequency of other druggable genes included BRCA1/2 (5%), BRAF (3%), HER2 amplifications (3%), MET amplifications (2%), ALK fusions (2%), RET fusions (0.7%), ROS1 fusions (0.7%), FGFR fusions (0.7%), NTRK fusion (0.6%). Frequency of GAs in druggable genes varied among different tumor types. For instance, EGFR mutations occurred in 49% of NSCLC, 7% of SCLC, 2% of gastric cancer, and 2% of CRC. NTRK fusions enriched in sarcoma (4%), gastric cancer (2%) and CRC (1%). The median TMB of the whole cohort was 4.6 muts/Mb and 6% had TMB higher than 20 muts/Mb. Top 3 tumors with highest median TMB were SCLC, CRC and gastric cancer, while pancreatic cancer and sarcoma had low TMB. As a pan-cancer biomarker for immunotherapy, pts with MSI-H accounted for 1.3% of solid tumors, including 9% of uterine neoplasms, 8% of CRC, 6% of gastric cancer and 2% of ICC. Conclusions: In summary, we have constructed a large-scale data set including somatic mutations, CNAs, fusions/rearrangements, TMB and MSI status from 5355 Chinese pts with more than 19 tumor types, which provided an extensive understanding of disease-specific indicators, outcomes and therapeutic strategies for both targeted and immune therapies in Chinese pts. Citation Format: Ming Yao, Minghui Wang, Mingwu Chen, Tao Shou, Jingyu Cao, Hui Chen, Aodi Wang, Lijuan Chen, Jinwei Hu, Shuirong Zhang, Kai Wang. Landscape of genomic alterations across solid tumors based on a comprehensive clinical sequencing analysis of 5355 Chinese cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5134." @default.
• W2955288519 created "2019-07-12" @default.
• W2955288519 creator A5011090841 @default.
• W2955288519 creator A5033465747 @default.
• W2955288519 creator A5036647389 @default.
• W2955288519 creator A5037657103 @default.
• W2955288519 creator A5049896182 @default.
• W2955288519 creator A5057632419 @default.
• W2955288519 creator A5060827269 @default.
• W2955288519 creator A5073531557 @default.
• W2955288519 creator A5074149482 @default.
• W2955288519 creator A5080199901 @default.
• W2955288519 creator A5086647275 @default.
• W2955288519 date "2019-07-01" @default.
• W2955288519 modified "2023-09-27" @default.
• W2955288519 title "Abstract 5134: Landscape of genomic alterations across solid tumors based on a comprehensive clinical sequencing analysis of 5355 Chinese cancer patients" @default.
• W2955288519 doi "https://doi.org/10.1158/1538-7445.am2019-5134" @default.
• W2955288519 hasPublicationYear "2019" @default.
• W2955288519 type Work @default.
• W2955288519 sameAs 2955288519 @default.
• W2955288519 citedByCount "0" @default.
• W2955288519 crossrefType "journal-article" @default.
• W2955288519 hasAuthorship W2955288519A5011090841 @default.
• W2955288519 hasAuthorship W2955288519A5033465747 @default.
• W2955288519 hasAuthorship W2955288519A5036647389 @default.
• W2955288519 hasAuthorship W2955288519A5037657103 @default.
• W2955288519 hasAuthorship W2955288519A5049896182 @default.
• W2955288519 hasAuthorship W2955288519A5057632419 @default.
• W2955288519 hasAuthorship W2955288519A5060827269 @default.
• W2955288519 hasAuthorship W2955288519A5073531557 @default.
• W2955288519 hasAuthorship W2955288519A5074149482 @default.
• W2955288519 hasAuthorship W2955288519A5080199901 @default.
• W2955288519 hasAuthorship W2955288519A5086647275 @default.
• W2955288519 hasConcept C104317684 @default.
• W2955288519 hasConcept C119054055 @default.
• W2955288519 hasConcept C121608353 @default.
• W2955288519 hasConcept C126322002 @default.
• W2955288519 hasConcept C135763542 @default.
• W2955288519 hasConcept C143998085 @default.
• W2955288519 hasConcept C153209595 @default.
• W2955288519 hasConcept C2780210213 @default.
• W2955288519 hasConcept C2780265364 @default.
• W2955288519 hasConcept C2781187634 @default.
• W2955288519 hasConcept C502942594 @default.
• W2955288519 hasConcept C526805850 @default.
• W2955288519 hasConcept C54355233 @default.
• W2955288519 hasConcept C71924100 @default.
• W2955288519 hasConcept C86803240 @default.
• W2955288519 hasConceptScore W2955288519C104317684 @default.
• W2955288519 hasConceptScore W2955288519C119054055 @default.
• W2955288519 hasConceptScore W2955288519C121608353 @default.
• W2955288519 hasConceptScore W2955288519C126322002 @default.
• W2955288519 hasConceptScore W2955288519C135763542 @default.
• W2955288519 hasConceptScore W2955288519C143998085 @default.
• W2955288519 hasConceptScore W2955288519C153209595 @default.
• W2955288519 hasConceptScore W2955288519C2780210213 @default.
• W2955288519 hasConceptScore W2955288519C2780265364 @default.
• W2955288519 hasConceptScore W2955288519C2781187634 @default.
• W2955288519 hasConceptScore W2955288519C502942594 @default.
• W2955288519 hasConceptScore W2955288519C526805850 @default.
• W2955288519 hasConceptScore W2955288519C54355233 @default.
• W2955288519 hasConceptScore W2955288519C71924100 @default.
• W2955288519 hasConceptScore W2955288519C86803240 @default.
• W2955288519 hasIssue "13_Supplement" @default.
• W2955288519 hasLocation W29552885191 @default.
• W2955288519 hasOpenAccess W2955288519 @default.
• W2955288519 hasPrimaryLocation W29552885191 @default.
• W2955288519 hasRelatedWork W1927386413 @default.
• W2955288519 hasRelatedWork W2112087504 @default.
• W2955288519 hasRelatedWork W2288492082 @default.
• W2955288519 hasRelatedWork W2620319885 @default.
• W2955288519 hasRelatedWork W2799708148 @default.
• W2955288519 hasRelatedWork W2983108327 @default.
• W2955288519 hasRelatedWork W3021515770 @default.
• W2955288519 hasRelatedWork W3026015583 @default.
• W2955288519 hasRelatedWork W4309046082 @default.
• W2955288519 hasRelatedWork W4386293350 @default.
• W2955288519 hasVolume "79" @default.
• W2955288519 isParatext "false" @default.
• W2955288519 isRetracted "false" @default.
• W2955288519 magId "2955288519" @default.
• W2955288519 workType "article" @default.